Oneness Biotech

4743.TWO

2.26 USD

-0.01

-0.44%

Overview

Last close

2.26 usd

Market cap

1.08B usd

52 week high

5.38 usd

52 week low

1.56 usd

Target price

9.85 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

287.4771

Price/Book Value

3.1426

Enterprise Value

878.30M usd

EV/Revenue

234.0839

EV/EBITDA

-91.0869

Key financials

Revenue TTM

3.75M usd

Gross Profit TTM

986728.49 usd

EBITDA TTM

-17.16M usd

Earnings per Share

-0.09 usd

Dividend

N/A usd

Total assets

388.42M usd

Net debt

N/A usd

About

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan. It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.